Search

Thank you to Amanda Bruno and our friends at the City of Tucson for featuring Reglagene in the latest episode of #BizBitesTucson! Please click the link below to watch the video.


https://www.youtube.com/watch?v=Zo3FynzCav0


Updated: Mar 28

Reglagene will be presenting at Pismo Ventures National Life Science Symposium on March 31st! Only 12 out of 98 companies were given this opportunity, and we are eager to share how we are fighting cancer safely!


To learn more about the event: https://lifescience.startupsymposium.com/

Updated: Mar 28

We congratulate Reglagene's Chief Scientific Officer Dr. Laurence Hurley for the granting of FDA Fast Track status for Pidnarulex, the only DNA quadruplex-targeting therapy that is active in human clinical trials. Pidnarulex is for ovarian and breast cancer patients presenting as BRCA1/2 or PALB2 positive. Dr. Hurley was the CSO at Cylene during the preclinical development of Pidnarulex. It is his second quadruplex therapy to reach clinical testing. Dr. Hurley won't stop his contributions to cancer treatments there and is actively working on developing a new brain cancer therapy with the Reglagene team!


https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-pidnarulex-in-brca1-2-palb2-ovarian-and-breast-cancer